Novel Antiviral Drugs Market, Global Outlook and Forecast 2022-2028

April 2022 | 67 pages | ID: NBBD7EC7985FEN
Market Monitor Global

Abstracts

The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.

This report contains market size and forecasts of Novel Antiviral Drugs in Global, including the following market information:

Global Novel Antiviral Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Novel Antiviral Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Reverse Transcriptase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Novel Antiviral Drugs include Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s and Gilead Sciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Novel Antiviral Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Novel Antiviral Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Novel Antiviral Drugs Market Segment Percentages, by Type, 2021 (%)

• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Fusion Inhibitors
• Immune System Modulators
• Other

Global Novel Antiviral Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Novel Antiviral Drugs Market Segment Percentages, by Application, 2021 (%)

• Hepatitis Therapeutics
• HIV/AIDS Therapeutics
• Herpes Therapeutics
• Influenza Therapeutics
• Other

Global Novel Antiviral Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Novel Antiviral Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Novel Antiviral Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Novel Antiviral Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche Holding AG
• GlaxoSmithKline
• Bristol-Myers Squibb
• AbbVie
• Johnson & Johnson
• Merck & Co
• Novartis
• Dr Reddy’s
• Gilead Sciences
• Aurobindo Pharma
• Cipla

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Novel Antiviral Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Novel Antiviral Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NOVEL ANTIVIRAL DRUGS OVERALL MARKET SIZE

2.1 Global Novel Antiviral Drugs Market Size: 2021 VS 2028
2.2 Global Novel Antiviral Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Novel Antiviral Drugs Players in Global Market
3.2 Top Global Novel Antiviral Drugs Companies Ranked by Revenue
3.3 Global Novel Antiviral Drugs Revenue by Companies
3.4 Top 3 and Top 5 Novel Antiviral Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Novel Antiviral Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Novel Antiviral Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Novel Antiviral Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Novel Antiviral Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Novel Antiviral Drugs Market Size Markets, 2021 & 2028
  4.1.2 Reverse Transcriptase Inhibitors
  4.1.3 Protease Inhibitors
  4.1.4 Fusion Inhibitors
  4.1.5 Immune System Modulators
  4.1.6 Other
4.2 By Type - Global Novel Antiviral Drugs Revenue & Forecasts
  4.2.1 By Type - Global Novel Antiviral Drugs Revenue, 2017-2022
  4.2.2 By Type - Global Novel Antiviral Drugs Revenue, 2023-2028
  4.2.3 By Type - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Novel Antiviral Drugs Market Size, 2021 & 2028
  5.1.2 Hepatitis Therapeutics
  5.1.3 HIV/AIDS Therapeutics
  5.1.4 Herpes Therapeutics
  5.1.5 Influenza Therapeutics
  5.1.6 Other
5.2 By Application - Global Novel Antiviral Drugs Revenue & Forecasts
  5.2.1 By Application - Global Novel Antiviral Drugs Revenue, 2017-2022
  5.2.2 By Application - Global Novel Antiviral Drugs Revenue, 2023-2028
  5.2.3 By Application - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Novel Antiviral Drugs Market Size, 2021 & 2028
6.2 By Region - Global Novel Antiviral Drugs Revenue & Forecasts
  6.2.1 By Region - Global Novel Antiviral Drugs Revenue, 2017-2022
  6.2.2 By Region - Global Novel Antiviral Drugs Revenue, 2023-2028
  6.2.3 By Region - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Novel Antiviral Drugs Revenue, 2017-2028
  6.3.2 US Novel Antiviral Drugs Market Size, 2017-2028
  6.3.3 Canada Novel Antiviral Drugs Market Size, 2017-2028
  6.3.4 Mexico Novel Antiviral Drugs Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Novel Antiviral Drugs Revenue, 2017-2028
  6.4.2 Germany Novel Antiviral Drugs Market Size, 2017-2028
  6.4.3 France Novel Antiviral Drugs Market Size, 2017-2028
  6.4.4 U.K. Novel Antiviral Drugs Market Size, 2017-2028
  6.4.5 Italy Novel Antiviral Drugs Market Size, 2017-2028
  6.4.6 Russia Novel Antiviral Drugs Market Size, 2017-2028
  6.4.7 Nordic Countries Novel Antiviral Drugs Market Size, 2017-2028
  6.4.8 Benelux Novel Antiviral Drugs Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Novel Antiviral Drugs Revenue, 2017-2028
  6.5.2 China Novel Antiviral Drugs Market Size, 2017-2028
  6.5.3 Japan Novel Antiviral Drugs Market Size, 2017-2028
  6.5.4 South Korea Novel Antiviral Drugs Market Size, 2017-2028
  6.5.5 Southeast Asia Novel Antiviral Drugs Market Size, 2017-2028
  6.5.6 India Novel Antiviral Drugs Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Novel Antiviral Drugs Revenue, 2017-2028
  6.6.2 Brazil Novel Antiviral Drugs Market Size, 2017-2028
  6.6.3 Argentina Novel Antiviral Drugs Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Novel Antiviral Drugs Revenue, 2017-2028
  6.7.2 Turkey Novel Antiviral Drugs Market Size, 2017-2028
  6.7.3 Israel Novel Antiviral Drugs Market Size, 2017-2028
  6.7.4 Saudi Arabia Novel Antiviral Drugs Market Size, 2017-2028
  6.7.5 UAE Novel Antiviral Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche Holding AG
  7.1.1 Roche Holding AG Corporate Summary
  7.1.2 Roche Holding AG Business Overview
  7.1.3 Roche Holding AG Novel Antiviral Drugs Major Product Offerings
  7.1.4 Roche Holding AG Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.1.5 Roche Holding AG Key News
7.2 GlaxoSmithKline
  7.2.1 GlaxoSmithKline Corporate Summary
  7.2.2 GlaxoSmithKline Business Overview
  7.2.3 GlaxoSmithKline Novel Antiviral Drugs Major Product Offerings
  7.2.4 GlaxoSmithKline Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.2.5 GlaxoSmithKline Key News
7.3 Bristol-Myers Squibb
  7.3.1 Bristol-Myers Squibb Corporate Summary
  7.3.2 Bristol-Myers Squibb Business Overview
  7.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Major Product Offerings
  7.3.4 Bristol-Myers Squibb Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.3.5 Bristol-Myers Squibb Key News
7.4 AbbVie
  7.4.1 AbbVie Corporate Summary
  7.4.2 AbbVie Business Overview
  7.4.3 AbbVie Novel Antiviral Drugs Major Product Offerings
  7.4.4 AbbVie Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.4.5 AbbVie Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Novel Antiviral Drugs Major Product Offerings
  7.5.4 Johnson & Johnson Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.5.5 Johnson & Johnson Key News
7.6 Merck & Co
  7.6.1 Merck & Co Corporate Summary
  7.6.2 Merck & Co Business Overview
  7.6.3 Merck & Co Novel Antiviral Drugs Major Product Offerings
  7.6.4 Merck & Co Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.6.5 Merck & Co Key News
7.7 Novartis
  7.7.1 Novartis Corporate Summary
  7.7.2 Novartis Business Overview
  7.7.3 Novartis Novel Antiviral Drugs Major Product Offerings
  7.7.4 Novartis Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.7.5 Novartis Key News
7.8 Dr Reddy’s
  7.8.1 Dr Reddy’s Corporate Summary
  7.8.2 Dr Reddy’s Business Overview
  7.8.3 Dr Reddy’s Novel Antiviral Drugs Major Product Offerings
  7.8.4 Dr Reddy’s Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.8.5 Dr Reddy’s Key News
7.9 Gilead Sciences
  7.9.1 Gilead Sciences Corporate Summary
  7.9.2 Gilead Sciences Business Overview
  7.9.3 Gilead Sciences Novel Antiviral Drugs Major Product Offerings
  7.9.4 Gilead Sciences Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.9.5 Gilead Sciences Key News
7.10 Aurobindo Pharma
  7.10.1 Aurobindo Pharma Corporate Summary
  7.10.2 Aurobindo Pharma Business Overview
  7.10.3 Aurobindo Pharma Novel Antiviral Drugs Major Product Offerings
  7.10.4 Aurobindo Pharma Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.10.5 Aurobindo Pharma Key News
7.11 Cipla
  7.11.1 Cipla Corporate Summary
  7.11.2 Cipla Business Overview
  7.11.3 Cipla Novel Antiviral Drugs Major Product Offerings
  7.11.4 Cipla Novel Antiviral Drugs Revenue in Global Market (2017-2022)
  7.11.5 Cipla Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Novel Antiviral Drugs Market Opportunities & Trends in Global Market
Table 2. Novel Antiviral Drugs Market Drivers in Global Market
Table 3. Novel Antiviral Drugs Market Restraints in Global Market
Table 4. Key Players of Novel Antiviral Drugs in Global Market
Table 5. Top Novel Antiviral Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Novel Antiviral Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Novel Antiviral Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Novel Antiviral Drugs Product Type
Table 9. List of Global Tier 1 Novel Antiviral Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Novel Antiviral Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Novel Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Novel Antiviral Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Novel Antiviral Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Novel Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Novel Antiviral Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Novel Antiviral Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Novel Antiviral Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Novel Antiviral Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Novel Antiviral Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Novel Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Novel Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Novel Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Novel Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Novel Antiviral Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Roche Holding AG Corporate Summary
Table 31. Roche Holding AG Novel Antiviral Drugs Product Offerings
Table 32. Roche Holding AG Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 33. GlaxoSmithKline Corporate Summary
Table 34. GlaxoSmithKline Novel Antiviral Drugs Product Offerings
Table 35. GlaxoSmithKline Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Bristol-Myers Squibb Corporate Summary
Table 37. Bristol-Myers Squibb Novel Antiviral Drugs Product Offerings
Table 38. Bristol-Myers Squibb Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 39. AbbVie Corporate Summary
Table 40. AbbVie Novel Antiviral Drugs Product Offerings
Table 41. AbbVie Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Novel Antiviral Drugs Product Offerings
Table 44. Johnson & Johnson Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Merck & Co Corporate Summary
Table 46. Merck & Co Novel Antiviral Drugs Product Offerings
Table 47. Merck & Co Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis Novel Antiviral Drugs Product Offerings
Table 50. Novartis Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Dr Reddy’s Corporate Summary
Table 52. Dr Reddy’s Novel Antiviral Drugs Product Offerings
Table 53. Dr Reddy’s Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Gilead Sciences Corporate Summary
Table 55. Gilead Sciences Novel Antiviral Drugs Product Offerings
Table 56. Gilead Sciences Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Aurobindo Pharma Corporate Summary
Table 58. Aurobindo Pharma Novel Antiviral Drugs Product Offerings
Table 59. Aurobindo Pharma Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Cipla Corporate Summary
Table 61. Cipla Novel Antiviral Drugs Product Offerings
Table 62. Cipla Novel Antiviral Drugs Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Novel Antiviral Drugs Segment by Type in 2021
Figure 2. Novel Antiviral Drugs Segment by Application in 2021
Figure 3. Global Novel Antiviral Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Novel Antiviral Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Novel Antiviral Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Novel Antiviral Drugs Revenue in 2021
Figure 8. By Type - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 12. US Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 24. China Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Novel Antiviral Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Novel Antiviral Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Holding AG Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. GlaxoSmithKline Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bristol-Myers Squibb Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. AbbVie Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck & Co Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Dr Reddy’s Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Gilead Sciences Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Aurobindo Pharma Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Cipla Novel Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)